Galectin Therapeutics reported $1.27M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Galectin Therapeutics USD 1.27M 220K Jun/2024
Gilead Sciences USD 247M 7M Jun/2026
Immunic 197K 222K Dec/2025
Incyte USD 582K 13K Jun/2026
Merck USD 525M 46M Jun/2026